Business
Shaare Zedek Medical Center Uses SOPHiA GENETICS to Advance Research of Myeloid Disorders
The hospital will use the SOPHiA DDM™ Platform to further its work with myeloid disorders and advance the development of precision medicine BOSTON and ROLLE,
About this update from Sophia Genetics Sa
[{"type":"text","content":"The hospital will use the SOPHiA DDM™ Platform to further its work with myeloid disorders and advance the development of precision medicine\nBOSTON and ROLLE, Switzerland, Sept. 29, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Shaare Zedek, the largest multi-disciplinary medical center in Jerusalem, is now live on the SOPHiA DDM™ Platform. The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine.\n\n \n \n \n \n \n \n\n \nMyeloid disorders affect millions of people worldwide, and while there are various types and classification of these disorders, collectively all myeloid disorders originate from hematopoietic disruptions in the myeloid lineage1. Because of the wide range of disorders and the complexity of these genetic mutations, treatment and therapy techniques evolve rapidly and are highly dependent on timely, cost-effective, and reliable sequencing strategies.\nShaare Zedek Medical Center has been providing top-level medical research and care for the people of Jerusalem since 1902. Today the hospital's name has become synonymous with advanced medicine, compassionate care, and many of the brightest medical minds in Israel. The use of SOPHiA GENETICS technology will allow Shaare Zedek to continue leading the way in Israel with cutting-edge technology aligned with the latest guidelines from the European Hematology Association (EHA).\n\"The last several years have shown rapid progress in targeted therapies for myeloid disorders,\" said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICS. \"With that progress has come an increase in international recommendations that can be challenging to keep up with. The implementation of the SOPHiA DDM™ Platform by Shaare Zedek will allow the hospital to keep pace with the progress while advancing its research to best serve its community.\"\nMolecular profiling via next-generation sequencing (NGS) is widely used to investigate the pathogenic variants causing different myeloid malignancies. However, NGS produces a vast amount of complex data. The SOPHiA DDM™ Platform is an NGS-based application that uses artificial intelligence (AI) to efficiently analyze and interpret raw NGS data for researcher...